- Home
- MYI vs MRVI Comparison
MYI vs MRVI Comparison
Compare MYI & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- MRVI
- Stock Information
- Founded
- MYI 1992
- MRVI 2020
- Country
- MYI United States
- MRVI United States
- Employees
- MYI N/A
- MRVI N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MYI Finance
- MRVI Health Care
- Exchange
- MYI Nasdaq
- MRVI Nasdaq
- Market Cap
- MYI 767.7M
- MRVI 676.6M
- IPO Year
- MYI N/A
- MRVI 2020
- Fundamental
- Price
- MYI $11.08
- MRVI $5.23
- Analyst Decision
- MYI
- MRVI Buy
- Analyst Count
- MYI 0
- MRVI 10
- Target Price
- MYI N/A
- MRVI $10.28
- AVG Volume (30 Days)
- MYI 256.7K
- MRVI 1.8M
- Earning Date
- MYI 01-01-0001
- MRVI 02-25-2025
- Dividend Yield
- MYI 4.81%
- MRVI N/A
- EPS Growth
- MYI N/A
- MRVI N/A
- EPS
- MYI N/A
- MRVI N/A
- Revenue
- MYI N/A
- MRVI $276,920,000.00
- Revenue This Year
- MYI N/A
- MRVI N/A
- Revenue Next Year
- MYI N/A
- MRVI $1.52
- P/E Ratio
- MYI N/A
- MRVI N/A
- Revenue Growth
- MYI N/A
- MRVI N/A
- 52 Week Low
- MYI $9.32
- MRVI $4.28
- 52 Week High
- MYI $11.70
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- MYI 48.71
- MRVI 48.29
- Support Level
- MYI $10.98
- MRVI $4.38
- Resistance Level
- MYI $11.11
- MRVI $6.21
- Average True Range (ATR)
- MYI 0.10
- MRVI 0.41
- MACD
- MYI 0.02
- MRVI -0.05
- Stochastic Oscillator
- MYI 62.16
- MRVI 46.45
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.